Skip to content

Financing biotech companies in a post-COVID-19 era


It is undeniable that the COVID-19 crisis has impacted many industries throughout the world, not least the biotech sector.

Join Euronext’s second Biotech Leaders Conference to hear from our panel of experts on the pandemic’s impact on both private and public biotech financing as well as the M&A market. Euronext will also present the findings from our Biotech Barometer H1 2020 and biotech investors survey.

Watch the webinar brought to you by EuronextKBC SecuritiesBioWin and Flanders.Bio by clicking the ‘START NOW’ button.

Our media partner for this webinar:

Topics covered in the webinar

  • The financing journey of Belgian biotech, argenx

  • Results from Euronext's Biotech Barometer H1 2020

  • Presentation of biotech investor survey

  • Q&A Session

Experts at your service

Benoît van den Hove

Benoît van den Hove

Head of Listing at Euronext Brussels


Eric Castaldi

Chief Financial Officer at argenx


Nicolas Meunier

Head of Advisory and IR Solutions at Euronext Corporate Services


Fabienne Van den Keere

Senior Advisor, Life Sciences at Korys

Cédric Moreau

Cédric Moreau

Partner at Sofinnova Partners

Bertrand Grimmonpré

Bertrand Grimmonpré

Chief Financial Officer at Miracor Medical

Nathalie Van den Haute

Nathalie Van den Haute

Executive Director Corporate Finance at KBC Securities

52118_EN-ECS-Post-Listing Advisory-update_GIF -2

About Post-Listing Advisory

Euronext Post-Listing Advisory offers a full range of services and a dedicated team to advise and assist companies in leveraging their listing life:
  • Strategic 360° listing diagnostics

  • Equity story review

  • IR action plan

  • Investor targeting

  • Market and listing analytics monitoring

  • Board level reports

Sign up now !

Back to the top